Claude did not invent scorpion antivenom

An investment research firm, Citrini Research, partnered with Anthropic to test whether an unreleased version of Claude could create a scorpion antivenom from scratch. The experiment generated 211 protein designs, of which 17 bound to scorpion toxins, but none bound to more than one toxin and none were tested for neutralization. Experts told The Verge that binding is the "easy" part and that translating binders into actual medicine remains a long, challenging process. The results were described as "technically promising" but "far from a medicine and hyped." Citrini, despite the scientific failure, framed the experiment as a success in terms of investment insight, highlighting companies involved in drug testing. The article notes that AI-enabled drug discovery still faces significant challenges in turning promising molecules into effective treatments.

(Source：The Verge)